Holen Sie sich die Stockscreener-App
3.63
1.63%
-0.06
Schlusskurs vom Vortag:
$3.69
Offen:
$3.6
24-Stunden-Volumen:
2.72M
Relative Volume:
0.72
Marktkapitalisierung:
$655.25M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-217.44M
KGV:
-1.6728
EPS:
-2.17
Netto-Cashflow:
$-205.20M
1W Leistung:
+7.72%
1M Leistung:
-35.06%
6M Leistung:
+211.59%
1J Leistung:
+22.22%
1-Tages-Spanne:
$3.43
$3.72
1-Wochen-Bereich:
$3.33
$4.04
52-Wochen-Spanne:
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Vergleichen Sie PRME mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.63 | 666.08M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
How interest rate cuts could boost Prime Medicine Inc. stockQuarterly Trade Summary & Intraday High Probability Alerts - newser.com
How strong is Prime Medicine Inc. stock balance sheetRate Hike & Growth Oriented Trading Recommendations - newser.com
Prime Medicine Target of Unusually High Options Trading (NYSE:PRME) - MarketBeat
How Prime Medicine Inc. stock reacts to job market dataJuly 2025 Analyst Calls & Daily Oversold Stock Bounce Ideas - newser.com
Prime Medicine transferred with Neutral rating at JPMorgan - MSN
Momentum divergence signals in Prime Medicine Inc. chartJuly 2025 Update & Trade Opportunity Analysis - newser.com
Prime Medicine’s Surprising Performance: Buy or Step Back? - StocksToTrade
Prime Medicine Inc. (PRME) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates - MSN
Published on: 2025-11-19 13:58:58 - newser.com
Prime Medicine (NASDAQ:PRME) Shares Down 5.8%What's Next? - MarketBeat
Prime Medicine (NYSE:PRME) Trading Down 6.1%Should You Sell? - MarketBeat
Technical signs of recovery in Prime Medicine Inc.July 2025 Intraday Action & Daily Stock Trend Reports - newser.com
Prime Medicine Enhances Cutting-Edge DNA Editing Methods - Kalkine Media
Tick level data insight on Prime Medicine Inc. volatilityJuly 2025 Retail & Technical Confirmation Trade Alerts - newser.com
Prime Medicine (NASDAQ:PRME) Shares Up 7.7%Should You Buy? - MarketBeat
Is Prime Medicine Inc. stock supported by strong fundamentalsEarnings Risk Summary & Real-Time Volume Analysis Alerts - newser.com
Is Prime Medicine Inc. stock a buy in volatile marketsWeekly Profit Analysis & High Return Stock Watch Alerts - newser.com
Published on: 2025-11-17 03:08:19 - newser.com
FY2025 EPS Estimate for Prime Medicine Increased by Analyst - MarketBeat
Can Prime Medicine Inc. stock outperform in 2025 bull market2025 Price Momentum & Fast Momentum Entry Tips - newser.com
How institutional ownership impacts Prime Medicine Inc. stockJuly 2025 Review & Entry Point Confirmation Alerts - newser.com
Combining price and volume data for Prime Medicine Inc.Market Trend Report & Capital Efficiency Focused Strategies - newser.com
Prime Medicine Bets On Gene Editing’s Next Big Leap - Finimize
FY2025 EPS Estimate for Prime Medicine Decreased by Analyst - MarketBeat
Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock - Investing.com Canada
Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline - TipRanks
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson DiseaseSlideshow - Seeking Alpha
Using economic indicators to assess Prime Medicine Inc. potentialEarnings Overview Summary & Expert Approved Momentum Ideas - newser.com
Chardan Capital Forecasts Prime Medicine FY2026 Earnings - MarketBeat
Prime Medicine (NYSE:PRME) Price Target Cut to $4.25 by Analysts at Citigroup - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading 7.1% HigherHere's Why - MarketBeat
Prime Medicine (NYSE:PRME) Trading Up 5.8%What's Next? - MarketBeat
Published on: 2025-11-12 13:12:15 - newser.com
Citigroup Maintains Neutral Rating on PRME with Lower Price Targ - GuruFocus
Prime Medicine’s Promising Advances in Gene Editing Justify Buy Rating - TipRanks
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):